Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + bisoprolol
- Development stage
- Phase 4
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dapagliflozin + bisoprolol is a fixed-dose combination therapy being developed by Servier for the treatment of heart failure. The combination targets two complementary pathways: SGLT2 inhibition and beta-adrenergic blockade. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces glucose reabsorption in the kidney, leading to glycosuria and providing significant cardiovascular benefits, including reduced preload and afterload. Bisoprolol is a selective beta-1 adrenergic receptor blocker that reduces heart rate and myocardial oxygen demand, which is a cornerstone of heart failure management. This combination therapy, associated with Servier's cardiovascular pipeline (which includes the Acertil brand), aims to provide synergistic effects in managing heart failure symptoms and improving patient outcomes through a simplified oral regimen.
- Other names
- dapagliflozin and bisoprololdapagliflozin/bisoprololbisoprolol/dapagliflozin
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)
Beyond the preview
Go deeper on dapagliflozin + bisoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + bisoprolol.